International Accord Gives US Firm Rights to Stem Cell Liver Cure

Stem Cell RegenCo and IIBM have entered into an exclusive joint venture giving liver damage patients a crucial alternative to a dangerous and uncertain liver transplant.

IIBM is headed by Gennady T. Sukhikh, MD, who, according to a Google computer search, is one of the world's foremost stem cell research specialists.

The focus of the agreement is to extend IIBM's Stem Cell Liver Regeneration (SCLR) procedure to the western world where due to the ban on embryonic stem cell research none currently exists.

A liver transplant is now the only treatment for acute and chronic liver failure.

The problems with these transplants are threefold: (1) there is a severe shortage of donor organs and thousands of patients die each year while awaiting an available donor liver; (2) the very great possibility the patient's body will reject the foreign liver; (3) even if the liver is not rejected the patients spend the rest of their lives on immuno-suppression drugs.

These drugs leave liver recipients open to infection and increase the risk of heart disease or cancer later in life. The cost of such drugs alone is $10,000 per year for life.

With the IIBM developed, non-invasive stem cell regeneration procedure, none of the above factors apply - no rejection possibilities, no immuno- suppression drugs or costs.

Shortly after the procedure, the patient will have a regenerated liver that replaces the old Hep B, C, cirrhosis or other diseased liver.

As confirmed by a multitude of clinical trials this procedure is effective and safe even in extreme emergencies such as end-stage liver disease.

Due to its non-surgical nature, it is particularly effective for treatment of children's liver problems.